Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member printed grouped question UIN question first answered answering member label attachment file name file name title title
tabling member	label

Search

516972

	registered interest
	date	03/05/2016
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Olympic Games: Brazil
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty’s Government, further to the Written Answers by Lord Prior of Brampton on 11 and 12 February (HL5764 and HL5766) and by Baroness Neville-Rolfe on 11 February (HL5765), and in the light of current information about the increased extent of dangers from the Zika virus affecting up to 20 per cent of all births, whether they intend to issue further advice about, or to reconsider, in consultation with other European governments, the long-term implications of participating in or attending the 2016 Olympic Games in Brazil.
	tabling member printed	Lord Maginnis of Drumglass
	uin	HL8128
	answer	answer is ministerial correction date of answer 11/05/2016 answer text <p>The British Olympic Association (BOA) and British Paralympic Association (BPA) have prepared guidance to consider the health risks, including those posed by Zika, for British athletes and staff travelling to Brazil for the Olympics.</p><p> </p><p>The Department of Health has convened an Olympics health advisory group on behalf of the Department for Culture, Media and Sport to focus on Zika and to support the BOA and BPA to ensure that they can continue to provide the best possible information and advice.</p><p> </p><p>The group will be chaired by the Department’s Chief Scientific Advisor, Professor Chris Whitty, and will bring together experts from the BOA and BPA as well as the London School of Hygiene and Tropical Medicine, University of Liverpool, University of Nottingham, the Royal Free London, Public Health England and across Government.</p><p> </p><p>Revisions of existing guidance or specific further advice will be published if it is deemed necessary.</p><p> </p><p>In the meantime, Public Health England and the National Travel Health Network and Centre (NaTHNaC) have developed and issued more general travel advice online to health professionals that is suitable for people travelling to Zika-affected countries, including pregnant women. A copy of the online advice is attached.</p><p> </p><p>This includes a list of countries where Zika virus transmission is occurring, advice around bite avoidance measures and what and who to speak to if those travelling have concerns. PHE and NaTHNaC continue to monitor the situation very closely and update advice as needed.</p> answering member printed Lord Prior of Brampton question first answered 11/05/2016 16:20:48 answering member 127 label Biography information for Lord Prior of Brampton attachment 1 file name zika-virus-update-and-advice-for-travellers-including-pregnant-women.pdf title Zika Virus travel advice
	tabling member	648 label Biography information for Lord Maginnis of Drumglass

621149

	registered interest
	date	25/10/2016
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Disability: Employment Schemes
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty’s Government what assessment they have made of the case for more resources to be made available for specialist support models for people with complex support needs, and who do not benefit from the Work and Health Programme.
	tabling member printed	Baroness Garden of Frognal
	uin	HL2666
	answer	answer is ministerial correction date of answer 08/11/2016 answer text <p>The Government recognises the challenges of helping those with the most complex health conditions move closer to work. The new Personal Support Package announced in <em>Improving Lives: The Work, Health and Disability </em>Green Paper introduces a range of new measures and interventions designed as part of a package of support which can be tailored to people’s individual needs. The offer, which applies to all Employment and Support Allowance claimants (and Universal Credit equivalents), includes personal support from disability trained, accredited work coaches, with a focus on mental health. Work coaches will be supported by an additional 300 Disability Employment Advisers and around 200 new community partners with disability expertise and local knowledge. This will lead to better signposting to other local voluntary and public sector services that may be available. A copy of the Green Paper is attached.</p><p> </p><p>The Government recognises that more needs to be done to help people stay well at work, including those with complex health conditions. The consultation on the Green Paper will help us to consider appropriate new models of support to help more people with disabilities or long term conditions to enter and remain in work.</p> answering member printed Lord Prior of Brampton question first answered 08/11/2016 15:08:55 answering member 127 label Biography information for Lord Prior of Brampton attachment 1 file name work-and-health-green-paper-print-version.pdf title HL2666 Green Paper
	tabling member	3842 label Biography information for Baroness Garden of Frognal

450641

	registered interest
	date	04/02/2016
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Accident and Emergency Departments
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty’s Government what steps they are taking to develop the model of co-location of urgent and emergency primary care service with accident and emergency departments.
	tabling member printed	Baroness Masham of Ilton
	uin	HL5942
	answer	answer is ministerial correction date of answer 11/02/2016 answer text <p>In August 2015, NHS England published <em>Safer, faster, better: good practice in delivering urgent and emergency care. </em>A copy is attached. This provides guidance to help frontline providers and commissioners re-design urgent and emergency care services, including considering locating urgent care centres in emergency departments.</p><p><em>Safer, faster, better</em> notes that urgent care centres co-located with emergency departments provide an opportunity to stream patients with less serious illnesses and injuries to a service that is resourced to meet their needs, while reducing crowding in emergency departments. It also sets out that to preserve flow, urgent care centre staff and cubicles must wherever possible be entirely separated from the majors/admission stream and that where urgent care centres are co-located with emergency departments, there must be appropriate integration, with shared governance arrangements and clearly defined protocols for the two-way transfer of patients.</p> answering member printed Lord Prior of Brampton question first answered 11/02/2016 12:53:09 answering member 127 label Biography information for Lord Prior of Brampton attachment 1 file name trans-uec - HL5942.pdf title Safer, Faster, Better
	tabling member	1850 label Biography information for Baroness Masham of Ilton

421268

	registered interest
	date	14/10/2015
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Hypothyroidism
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty’s Government what steps they have taken to help patients with undiagnosed hypothyroidism who present clinical signs and symptoms of that condition, but are refused any treatment as their blood test results remain normal.
	tabling member printed	Lord Pendry
	uin	HL2639
	answer	answer is ministerial correction date of answer 27/10/2015 answer text <p>A blood test measuring hormone levels is the only accurate way to find out if there is a thyroid problem.</p><br /><p>Best practice on the identification and management of hypothyroidism has been set out by the Royal College of Physicians (RCP) in its guidance, <em>The Diagnosis and Management of Primary Hypothyroidism</em>, first published in 2008. The guidance, which is attached, was developed on behalf of key organisations, including the British Thyroid Association (BTA), the British Thyroid Foundation (BTF) and the Society for Endocrinology (SOE), and is endorsed by the Royal College of General Practitioners. A copy of the UK Guidelines is attached.</p><br /><p>The RCP guidance sets out that the only validated method of testing thyroid function is through a blood sample, which must include measurement of the levels of thyroid‐stimulating hormone (TSH) and free thyroxine (FT4) in serum, as recommended in the <em>UK Guidelines for the Use of Thyroid Function Tests</em> published by the BTA.</p><br /><p>The RCP guidelines set out that overwhelming evidence supports the use of thyroxine hormone replacement (T4 or tetra-iodothyronine) alone in the treatment of hypothyroidism, with this usually being prescribed as levothyroxine. However, this does not prevent clinicians considering other forms of thyroid hormone replacement if appropriate.</p><p>The guidance remains up-to-date and a statement from the BTA Executive Committee supporting the existing guidelines was published in May 2015 in <em>Clinical Endocrinology</em> and endorsed by the Association for Clinical Biochemistry and Laboratory Medicine, the BTF, the RCP and the SOE. The full statement is attached and available online at:</p><br /><p><a href="http://onlinelibrary.wiley.com/doi/10.1111/cen.12824/full" target="_blank">http://onlinelibrary.wiley.com/doi/10.1111/cen.12824/full</a></p><br /><p>Regarding international guidance and harmonisation on approaches to testing, the existing United Kingdom guidelines have now been supported by new guidance published in the United States of America which draws on the latest research and available evidence on the management of the condition. The USA guidance also includes a section on the ethics of prescribing thyroid hormone combination therapies when the potential long-term harmful effects are not known.</p> answering member printed Lord Prior of Brampton attachment 1 file name Okosieme_et_al-2015-Clinical_Endocrinology.pdf title Clinical Endocrinology paper 2 file name the-diagnosis-and-management-of-primary-hypothyroidism-revised-statement-14-june-2011_2.pdf title Royal College of Physicians guidance 3 file name TFT_guideline_final_version_July_2006.pdf title UK Guidelines Thyroid Function Tests grouped question UIN HL2640 HL2641 HL2642 question first answered 27/10/2015 17:53:42 answering member 127 label Biography information for Lord Prior of Brampton
	tabling member	457 label Biography information for Lord Pendry

421269

	registered interest
	date	14/10/2015
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Hypothyroidism
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty’s Government whether there are any plans to amend the diagnosis of hypothyroidism, which under current guidance is based solely on a blood test.
	tabling member printed	Lord Pendry
	uin	HL2640
	answer	answer is ministerial correction date of answer 27/10/2015 answer text <p>A blood test measuring hormone levels is the only accurate way to find out if there is a thyroid problem.</p><br /><p>Best practice on the identification and management of hypothyroidism has been set out by the Royal College of Physicians (RCP) in its guidance, <em>The Diagnosis and Management of Primary Hypothyroidism</em>, first published in 2008. The guidance, which is attached, was developed on behalf of key organisations, including the British Thyroid Association (BTA), the British Thyroid Foundation (BTF) and the Society for Endocrinology (SOE), and is endorsed by the Royal College of General Practitioners. A copy of the UK Guidelines is attached.</p><br /><p>The RCP guidance sets out that the only validated method of testing thyroid function is through a blood sample, which must include measurement of the levels of thyroid‐stimulating hormone (TSH) and free thyroxine (FT4) in serum, as recommended in the <em>UK Guidelines for the Use of Thyroid Function Tests</em> published by the BTA.</p><br /><p>The RCP guidelines set out that overwhelming evidence supports the use of thyroxine hormone replacement (T4 or tetra-iodothyronine) alone in the treatment of hypothyroidism, with this usually being prescribed as levothyroxine. However, this does not prevent clinicians considering other forms of thyroid hormone replacement if appropriate.</p><p>The guidance remains up-to-date and a statement from the BTA Executive Committee supporting the existing guidelines was published in May 2015 in <em>Clinical Endocrinology</em> and endorsed by the Association for Clinical Biochemistry and Laboratory Medicine, the BTF, the RCP and the SOE. The full statement is attached and available online at:</p><br /><p><a href="http://onlinelibrary.wiley.com/doi/10.1111/cen.12824/full" target="_blank">http://onlinelibrary.wiley.com/doi/10.1111/cen.12824/full</a></p><br /><p>Regarding international guidance and harmonisation on approaches to testing, the existing United Kingdom guidelines have now been supported by new guidance published in the United States of America which draws on the latest research and available evidence on the management of the condition. The USA guidance also includes a section on the ethics of prescribing thyroid hormone combination therapies when the potential long-term harmful effects are not known.</p> answering member printed Lord Prior of Brampton attachment 1 file name Okosieme_et_al-2015-Clinical_Endocrinology.pdf title Clinical Endocrinology paper 2 file name the-diagnosis-and-management-of-primary-hypothyroidism-revised-statement-14-june-2011_2.pdf title Royal College of Physicians guidance 3 file name TFT_guideline_final_version_July_2006.pdf title UK Guidelines Thyroid Function Tests grouped question UIN HL2639 HL2641 HL2642 question first answered 27/10/2015 17:53:42 answering member 127 label Biography information for Lord Prior of Brampton
	tabling member	457 label Biography information for Lord Pendry

421270

	registered interest
	date	14/10/2015
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Hypothyroidism
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty’s Government what progress is being made on the initiative to achieve greater harmonisation on approaches to diagnosing hypothyroidism internationally.
	tabling member printed	Lord Pendry
	uin	HL2641
	answer	answer is ministerial correction date of answer 27/10/2015 answer text <p>A blood test measuring hormone levels is the only accurate way to find out if there is a thyroid problem.</p><br /><p>Best practice on the identification and management of hypothyroidism has been set out by the Royal College of Physicians (RCP) in its guidance, <em>The Diagnosis and Management of Primary Hypothyroidism</em>, first published in 2008. The guidance, which is attached, was developed on behalf of key organisations, including the British Thyroid Association (BTA), the British Thyroid Foundation (BTF) and the Society for Endocrinology (SOE), and is endorsed by the Royal College of General Practitioners. A copy of the UK Guidelines is attached.</p><br /><p>The RCP guidance sets out that the only validated method of testing thyroid function is through a blood sample, which must include measurement of the levels of thyroid‐stimulating hormone (TSH) and free thyroxine (FT4) in serum, as recommended in the <em>UK Guidelines for the Use of Thyroid Function Tests</em> published by the BTA.</p><br /><p>The RCP guidelines set out that overwhelming evidence supports the use of thyroxine hormone replacement (T4 or tetra-iodothyronine) alone in the treatment of hypothyroidism, with this usually being prescribed as levothyroxine. However, this does not prevent clinicians considering other forms of thyroid hormone replacement if appropriate.</p><p>The guidance remains up-to-date and a statement from the BTA Executive Committee supporting the existing guidelines was published in May 2015 in <em>Clinical Endocrinology</em> and endorsed by the Association for Clinical Biochemistry and Laboratory Medicine, the BTF, the RCP and the SOE. The full statement is attached and available online at:</p><br /><p><a href="http://onlinelibrary.wiley.com/doi/10.1111/cen.12824/full" target="_blank">http://onlinelibrary.wiley.com/doi/10.1111/cen.12824/full</a></p><br /><p>Regarding international guidance and harmonisation on approaches to testing, the existing United Kingdom guidelines have now been supported by new guidance published in the United States of America which draws on the latest research and available evidence on the management of the condition. The USA guidance also includes a section on the ethics of prescribing thyroid hormone combination therapies when the potential long-term harmful effects are not known.</p> answering member printed Lord Prior of Brampton attachment 1 file name Okosieme_et_al-2015-Clinical_Endocrinology.pdf title Clinical Endocrinology paper 2 file name the-diagnosis-and-management-of-primary-hypothyroidism-revised-statement-14-june-2011_2.pdf title Royal College of Physicians guidance 3 file name TFT_guideline_final_version_July_2006.pdf title UK Guidelines Thyroid Function Tests grouped question UIN HL2639 HL2640 HL2642 question first answered 27/10/2015 17:53:43 answering member 127 label Biography information for Lord Prior of Brampton
	tabling member	457 label Biography information for Lord Pendry

421271

	registered interest
	date	14/10/2015
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Hypothyroidism
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty’s Government whether there are any plans to amend the treatment of hypothyroidism by including thyroid hormone combination therapies other than treatment by levothyroxine in the standard of care.
	tabling member printed	Lord Pendry
	uin	HL2642
	answer	answer is ministerial correction date of answer 27/10/2015 answer text <p>A blood test measuring hormone levels is the only accurate way to find out if there is a thyroid problem.</p><br /><p>Best practice on the identification and management of hypothyroidism has been set out by the Royal College of Physicians (RCP) in its guidance, <em>The Diagnosis and Management of Primary Hypothyroidism</em>, first published in 2008. The guidance, which is attached, was developed on behalf of key organisations, including the British Thyroid Association (BTA), the British Thyroid Foundation (BTF) and the Society for Endocrinology (SOE), and is endorsed by the Royal College of General Practitioners. A copy of the UK Guidelines is attached.</p><br /><p>The RCP guidance sets out that the only validated method of testing thyroid function is through a blood sample, which must include measurement of the levels of thyroid‐stimulating hormone (TSH) and free thyroxine (FT4) in serum, as recommended in the <em>UK Guidelines for the Use of Thyroid Function Tests</em> published by the BTA.</p><br /><p>The RCP guidelines set out that overwhelming evidence supports the use of thyroxine hormone replacement (T4 or tetra-iodothyronine) alone in the treatment of hypothyroidism, with this usually being prescribed as levothyroxine. However, this does not prevent clinicians considering other forms of thyroid hormone replacement if appropriate.</p><p>The guidance remains up-to-date and a statement from the BTA Executive Committee supporting the existing guidelines was published in May 2015 in <em>Clinical Endocrinology</em> and endorsed by the Association for Clinical Biochemistry and Laboratory Medicine, the BTF, the RCP and the SOE. The full statement is attached and available online at:</p><br /><p><a href="http://onlinelibrary.wiley.com/doi/10.1111/cen.12824/full" target="_blank">http://onlinelibrary.wiley.com/doi/10.1111/cen.12824/full</a></p><br /><p>Regarding international guidance and harmonisation on approaches to testing, the existing United Kingdom guidelines have now been supported by new guidance published in the United States of America which draws on the latest research and available evidence on the management of the condition. The USA guidance also includes a section on the ethics of prescribing thyroid hormone combination therapies when the potential long-term harmful effects are not known.</p> answering member printed Lord Prior of Brampton attachment 1 file name Okosieme_et_al-2015-Clinical_Endocrinology.pdf title Clinical Endocrinology paper 2 file name the-diagnosis-and-management-of-primary-hypothyroidism-revised-statement-14-june-2011_2.pdf title Royal College of Physicians guidance 3 file name TFT_guideline_final_version_July_2006.pdf title UK Guidelines Thyroid Function Tests grouped question UIN HL2639 HL2640 HL2641 question first answered 27/10/2015 17:53:43 answering member 127 label Biography information for Lord Prior of Brampton
	tabling member	457 label Biography information for Lord Pendry

425861

	registered interest
	date	03/11/2015
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Cancer: Diagnosis
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty’s Government what action they are taking to improve rates of early diagnosis of cancer.
	tabling member printed	Lord Hunt of Kings Heath
	uin	HL3259
	answer	answer is ministerial correction date of answer 12/11/2015 answer text <p>Improving early diagnosis of cancer is a priority for this Government. We will continue to work with NHS England, Public Health England and other partners to achieve early diagnosis through improved screening programmes, Be Clear on Cancer campaigns to raise awareness of signs and symptoms of cancer to encourage people with signs and symptoms to present promptly to their general practitioner (GP), and help for GPs to refer more accurately.</p><br /><p>We have committed to implementing recommendation 24 of the Independent Cancer Taskforce’s report that by 2020, everyone referred with a suspicion of cancer will receive either a definitive diagnosis or the all-clear within four weeks. NHS England is working with partners across the health system to consider how best to take this forward. A copy of the Taskforce’s report <em>Achieving World-Class Outcomes: A Strategy for England 2015-2020, </em>is attached.</p><p>NHS England has launched a major early diagnosis programme, Accelerate, Co-ordinate, Evaluate (ACE), working jointly with Cancer Research UK and Macmillan Cancer Support to test new innovative approaches to identifying cancer more quickly. Outputs from the first wave of test sites, which commenced in April 2015, will be delivered on a phased basis, with the majority falling between September 2015 and December 2016. It is expected that ACE Wave 1 evaluation will be complete by mid-2017. An ACE Wave 2 is being planned.</p><br /><p>In June this year, the National Institute for Health and Care Excellence published an updated guideline ‘Suspected cancer: recognition and referral’. The guideline focuses on key symptoms, to make it easier to use and will continue to support GPs to identify patients with signs and symptoms of suspected cancer, and urgently refer them as appropriate. The guideline recommends a lower referral threshold for urgent referrals where cancer is suspected. A copy of the guideline is also attached.</p><p><strong></strong></p><p><strong></strong></p><p><strong></strong></p> answering member printed Lord Prior of Brampton attachment 1 file name achieving_world-class_cancer_outcomes_-_a_strategy_for_england_2015-2020.pdf title Achieving World Class Outcomes 2 file name suspected-cancer-recognition-and-referral-1837268071621.pdf title Suspected cancer question first answered 12/11/2015 13:06:02 answering member 127 label Biography information for Lord Prior of Brampton
	tabling member	2024 label Biography information for Lord Hunt of Kings Heath

637284

	registered interest
	date	15/11/2016
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Health Services: Travellers
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty’s Government, further to the Written Answer by Lord Prior of Brampton on 8 November (HL2865), what steps have been taken to encourage joined up working by local authorities, the National Health Service and responsible health agencies, and local public health services to improve the health outcomes of Gypsies and Travellers.
	tabling member printed	Baroness Hodgson of Abinger
	uin	HL3209
	answer	answer is ministerial correction date of answer 24/11/2016 answer text <p>The <em>NHS Five Year Forward View</em> (2014) sets out the ambition to improve the nation’s health and reduce inequalities, including among the most vulnerable groups. Through the inequality duties introduced through the 2012 Health and Social Care Act, local areas must have regard to inequalities in access to, and the outcomes from, National Health Service services in developing their plans. Clinical commissioning groups (CCGs), health and wellbeing boards and the rest of the local health system work together to undertake joint strategic needs assessments of local health needs and develop strategic plans, working with key stakeholders to deliver outcomes and reduce health inequalities. <strong> </strong></p><p> </p><p>All CCGs are provided with local and national data from Public Health England and NHS England to support the planning and commissioning process. These tools help to identify differences in access to services and health outcomes across the local population, including among vulnerable groups. For example, on-line resources available to local areas include Commissioning for Value Packs, the NHS Atlas of Variation in Healthcare, and the Marmot indicator local authority profiles.</p><p> </p><p>Guidance on addressing the health needs of vulnerable groups including Gypsies and Travellers was developed under the DH-sponsored inclusion health programme. It included <em>Inclusion of Gypsy Traveller health needs in Joint Strategic Needs Assessments: A review</em>, a report compiled by Friends, Families and Travellers (2015), <em>Standards for commissioners and service providers</em>, by the Faculty for Homeless and Inclusion Health (2013) and <em>Improving access to health care for Gypsies and Travellers, homeless people and sex workers</em>, by Royal College of General Practitioners (2013). Copies of these documents are attached. NHS England published guidance for the service on the rights of vulnerable groups in registering with GPs to reduce the risk of exacerbating health inequalities for vulnerable groups, <em>Patient Registration: Standard Operating Principles for Primary Medical Care (General Practice)</em>, NHS England, 2015. A copy has been placed in the library.</p><p> </p> answering member printed Lord Prior of Brampton attachment 1 file name Improving access to healthcare.pdf title Improving access to healthcare 2 file name standards for commissioners.pdf title Standards for commissioners 3 file name Inclusion of Gypsy Traveller health needs.pdf title Inclusion of Gypsy Traveller health needs question first answered 24/11/2016 15:22:58 answering member 127 label Biography information for Lord Prior of Brampton
	tabling member	4301 label Biography information for Baroness Hodgson of Abinger

422466

	registered interest
	date	20/10/2015
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Hepatitis
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty’s Government, to date, how many patients have commenced treatment under NHS England's commissioning policy for the treatment of cirrhosis in adults with hepatitis C, and how much that commissioning policy has cost.
	tabling member printed	Baroness Masham of Ilton
	uin	HL2791
	answer	answer is ministerial correction date of answer 02/11/2015 answer text <p>NHS England has invested in two policies enabling access to some of the new treatments (in advance of the publication of National Institute for Health and Care Excellence technology appraisals) for patients with hepatitis C with the greatest clinical need.</p><p>NHS England’s Interim Clinical Commissioning Policy Statement of April 2014 provided an Early Access Scheme for around 1,000 patients with decompensated cirrhosis. Then in June 2015, NHS England extended that policy so the next group of patients with the greatest clinical need, those with cirrhosis, could also benefit from the new Direct Acting Antivirals. A copy of both of these policies has been attached.</p><p>Between publication of the cirrhosis policy in June and 19 October, NHS England received over 1,900 notifications of decisions to treat under the policy. These notifications are submitted by treating clinicians and confirm that patients meet the policy criteria.</p><p>In order to confirm the actual cost of this policy, NHS England needs to complete a process of validating treatment notifications against actual trust reported activity and invoicing data on dispensed drugs. These data sources are submitted at different times and so an accurate assessment of the cost of the policy to date will not be able to be possible until the end of the year. Any data shared on the cost of the policy will need to observe commercial in confidence pricing agreements.</p><p>Based on preliminary modelling, NHS England set aside £190 million in 2015-16 for the treatment of hepatitis C.</p> answering member printed Lord Prior of Brampton attachment 1 file name sofosbuvir-pol-stat.pdf title Sofosbuvir Policy Statement 2 file name hep-c-cirrhosis-polcy-statmnt-0615.pdf title Hep C Policy Statement question first answered 02/11/2015 16:47:03 answering member 127 label Biography information for Lord Prior of Brampton
	tabling member	1850 label Biography information for Baroness Masham of Ilton